000 01512 a2200409 4500
005 20250514002940.0
264 0 _c20010927
008 200109s 0 0 eng d
022 _a0889-2229
024 7 _a10.1089/088922201750251981
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRiddell, L A
245 0 0 _aA phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease.
_h[electronic resource]
260 _bAIDS research and human retroviruses
_cJun 2001
300 _a789-97 p.
_bdigital
500 _aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAIDS-Related Opportunistic Infections
_xprevention & control
650 0 4 _aAnti-Infective Agents
_xadverse effects
650 0 4 _aConsumer Product Safety
650 0 4 _aDouble-Blind Method
650 0 4 _aHIV-1
650 0 4 _aHumans
650 0 4 _aInterferon-gamma
_xadverse effects
650 0 4 _aRecombinant Proteins
700 1 _aPinching, A J
700 1 _aHill, S
700 1 _aNg, T T
700 1 _aArbe, E
700 1 _aLapham, G P
700 1 _aAsh, S
700 1 _aHillman, R
700 1 _aTchamouroff, S
700 1 _aDenning, D W
700 1 _aParkin, J M
773 0 _tAIDS research and human retroviruses
_gvol. 17
_gno. 9
_gp. 789-97
856 4 0 _uhttps://doi.org/10.1089/088922201750251981
_zAvailable from publisher's website
999 _c11358506
_d11358506